NCT04004910 is a Phase 1, PHASE2 clinical trial of Plasma soluble TNF receptor pulldown in Advanced Breast Cancer, sponsored by Immunicom Inc.

Who is sponsoring NCT04004910?

NCT04004910 is sponsored by Immunicom Inc.

What drugs are being tested in NCT04004910?

Interventions in NCT04004910: Plasma soluble TNF receptor pulldown, Plasma soluble TNF receptor pulldown + chemotherapy, Chemotherapy Drugs, Cancer.

What condition does NCT04004910 study?

NCT04004910 studies Advanced Breast Cancer.

Is NCT04004910 still recruiting?

NCT04004910 is currently status unknown. Last updated 24 March 2022.

Last reviewed 2022-03-24 · How we verify

NCT04004910

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study Comparing Immunopheresis® Alone or In Combination With Chemotherapy Versus Chemotherapy Alone in Treatment of Advanced Breast Cancer Patients

Status unknown Phase 1, PHASE2 Last updated 24 March 2022

What this trial tests

Phase 1, PHASE2 trial testing Plasma soluble TNF receptor pulldown in Advanced Breast Cancer in 170 participants. Status unknown.

Timeline

31 May 2019

Primary endpoint
31 December 2022

31 July 2023

Quick facts

Lead sponsor	Immunicom Inc
Phase	Phase 1, PHASE2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	170
Start date	31 May 2019
Primary completion	31 December 2022
Estimated completion	31 July 2023
Sites	5 locations across Turkey (Türkiye), Poland

Drugs / interventions tested

Plasma soluble TNF receptor pulldown
Plasma soluble TNF receptor pulldown + chemotherapy
Chemotherapy Drugs, Cancer — full drug profile →

Conditions studied

Advanced Breast Cancer — all drugs for Advanced Breast Cancer →

Sponsor

Immunicom Inc — full company profile →

Who can join

18 and older, female only, with Advanced Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a multicenter, open-label, Phase 1/ 2 study to evaluate the short-term and longer-term safety, tolerability, and effectiveness of Immunopheresis® with the LW-02 column in removal of Soluble Tumor Necrosis Factor Receptors (sTNF-Rs) from plasma of patients with advanced, refractory Breast Cancer (BC) and for disease control when employed as monotherapy, or in combination with a low dose chemotherapy. A low dose chemotherapy will serve as control.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Type 1 and type 2 cytokine-mediated immune orchestration in the tumour microenvironment and their therapeutic potential.
Jou E. · · 2023 · cited 13× · PMID 37455828 · DOI 10.37349/etat.2023.00146
Cytokine Networks in Triple-Negative Breast Cancer: Mechanisms, Therapeutic Targets, and Emerging Strategies.
Rosado-Sanz M, Martínez-Alarcón N, Abellán-Soriano A, Golfe R, et al · · 2025 · cited 2× · PMID 40868199 · DOI 10.3390/biomedicines13081945

Verify or expand the search:

Other recruiting trials for Advanced Breast Cancer

Currently open trials in the same condition.

NCT07408089 — Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer · Phase 1 · recruiting
NCT07318805 — A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors · Phase 1 · recruiting
NCT07259226 — Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful Biomarkers · Phase 2 · recruiting
NCT06982521 — Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PI · Phase 3 · recruiting
NCT07428655 — Acceptability and Feasibility of PSC Model of Serious Illness Communication · NA · active not recruiting

Other Immunicom Inc trials

Trials by the same sponsor.

NCT04690686 — Immunopheresis Alone or in Combination With Paclitaxel or Atezolizumab in Non-small Cell Lung Cancer (NSCLC). · Phase 2 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04004910 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Immunicom Inc
Last refreshed: 24 March 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04004910.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing